Role of protein tyrosine kinase-2 in gynecological tumors

doi:10.16352/j.issn.1001-6325.2025.08.1098

Abstract

Abstract: Protein tyrosine kinase 2 (PTK2) is an important non-receptor tyrosine kinase that functions through both kinase-dependent and kinase-independent pathways. PTK2 can activate the downstream pathways through integrin-mediated adhesion signal transduction, regulating tumor cell proliferation, migration and epithelial-mesenchymal transition (EMT). Additionally, PTK2 can also remodel the tumor microenvironment, promote tumor metastasis, angiogenesis and immune escape. A large number of studies have shown that PTK2 is highly expressed in various gynecological cancers, and its expression level is significantly associated with tumor stage, poor prognosis and clinical drug resistance. Therefore, PTK2 is expected to serve as a novel therapeutic target and prognostic biomarker for gynecological malignancies in the future.

Key words: malignant gynecological tumor, focal adhesion kinase, tumor metastasis, signal pathway, PTK2 inhibitor

CLC Number:

QIN Yi, WANG Xiaoyan. Role of protein tyrosine kinase-2 in gynecological tumors[J]. Basic & Clinical Medicine, 2025, 45(8): 1098-1102.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74:229-263.
[2] Hu HH, Wang SQ, Shang HL, et al. Roles and inhibitors of FAK in cancer: current advances and future directions[J].Front Pharmacol,2024,15:1274209.doi: 10.3389/fphar.2024.1274209.
[3] Pomella S, Cassandri M, Braghini MR, et al. New insights on the nuclear functions and targeting of FAK in cancer[J]. Int J Mol Sci, 2022, 23: 1998.doi: 10.3390/ijms23041998.
[4] Webb ER, Black A, Barth ND, et al. The integrin adhesome and control of anti-tumour immunity[J]. Biochem Soc Trans, 2024, 52: 2455-2468.
[5] Chen S, He T, Zhong Y, et al. Roles of focal adhesion proteins in skeleton and diseases[J]. Acta Pharm Sin B, 2023, 13:998-1013.
[6] Song X, Xu H, Wang P, et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation[J]. J Hepatol, 2021, 75: 888-899.
[7] Sharma BK, Mureb D, Murab S, et al. Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth[J]. J Thromb Haemost, 2021, 19: 2480-2494.
[8] Raji L, Tetteh A, Amin ARMR. Role of c-Src in carcinogenesis and drug resistance[J]. Cancers (Basel), 2023, 16: 32.doi:10.3390/concers16010032.
[9] Huang YH, Chen HK, Hsu YF, et al. Src-FAK signaling mediates interleukin 6-induced HCT116 colorectal cancer epithelial-mesenchymal transition[J]. Int J Mol Sci, 2023, 24: 6650.doi: 10.3390/ijms24076650.
[10] Pan R, Yu Y, Zhu H, et al. RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation[J]. iScience, 2022, 25: 105184. doi: 10.1016/j.isci.2022.105184.
[11] Canel M, Sławińska AD, Lonergan DW,et al. FAK sup-presses antigen processing and presentation to promote immune evasion in pancreatic cancer[J]. Gut, 2023, 73: 131-155.
[12] Wu HJ, Hao M, Yeo SK, et al. FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication[J]. Oncogene, 2020, 39: 2539-2549.
[13] Huang C, Wang Y, Huang JH, et al. Sema3A drastically suppresses tumor growth in oral cancer xenograft model of mice[J]. BMC Pharmacol Toxicol, 2017, 18:55.doi: 10.1186/s40360-017-0163-4.
[14] 候壹颖,魏芳. BUB1B与妇科恶性肿瘤[J]. 基础医学与临床,2024,44:1717-1721.
[15] 封菊,苑中甫,邱海峰. RNA干扰FAK表达抑制宫颈癌细胞侵袭、迁移能力的研究[J]. 癌症进展,2018,16:179-182.
[16] Zhang J, Li X, Zhou Y, et al. FNBP1 facilitates cervical cancer cell survival by the constitutive activation of FAK/PI3K/AKT/mTOR signaling[J]. Cells, 2023, 12: 1964.doi: 10.3390/cells12151964.
[17] Du Q, Liu P, Zhang C, et al. FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis[J]. Cell Death Dis, 2022, 13: 488.doi: 10.1038/s41419-022-04926-2.
[18] Gong H, Zhao L, Liu J. Protective effect of tretinoin on cervical cancer growth and proliferation through downregulation of pFAK2 expression[J]. Environ Toxicol, 2024, 39: 2732-2740.
[19] Dong P, Xiong Y, Konno Y, et al. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway[J]. J Exp Clin Cancer Res, 2021, 40: 216.doi: 10.1186/s13046-021-02018-1.
[20] Lopez-Mejia IC, Pijuan J, Navaridas R, et al. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness[J]. Mol Oncol, 2023, 17: 98-118.
[21] Huang YH, Wang WL, Wang PH, et al. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis[J]. Int J Biol Sci, 2024, 20: 265-279.
[22] Demirkiran C, Greenman M, Bellone S, et al. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas[J]. Gynecol Oncol, 2024, 187: 12-20.
[23] 霍茜瑜, 任彦松. 纤维连接蛋白在卵巢癌迁移侵袭中作用的研究进展[J]. 现代肿瘤医学, 2024, 32: 1935-1938.
[24] Ozmadenci D, Shankara Narayanan JS, Andrew J, et al. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis[J]. Proc Natl Acad Sci USA, 2022, 119: e2117065119.doi: 10.1073/pnas.2117065119.
[25] Xie G, Zhang Y, Ma J, et al. Exosomal AHSG in ovarian cancer ascites inhibits malignant progression of ovarian cancer by p53/FAK/Src signaling[J]. Transl Cancer Res, 2024, 13: 5365-5380.
[26] Wu X, Wang J, Liang Q, et al. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment[J]. Biomed Pharmacother, 2022, 151: 113116.doi: 10.1016/j.biopha.2022.113116.